German Merck watches evobrutinib’s benefit melt away
Merck KGaA’s BTK inhibitor had been hailed as the first to show activity in multiple sclerosis, but full clinical results cast doubt on this claim.
Asco 2019 – tepotinib and capmatinib fight over a new lung cancer niche
cMet emerges as the latest genetic mutation that could soon see targeted treatments become available.
Go or no go? Merck, Regeneron and Alexion await US expansion
Approvals for new uses of old drugs should far outweigh nods for novel projects in June.
Merck sees potential in Peloton
Peloton Therapeutics’ approach to fighting kidney tumours has apparently convinced Merck & Co, which is to pay $1.05bn for the company on the back of relatively…
Poxel tastes sweet success at last
The group follows licensing deals with Dainippon and Roivant with a pivotal study win.
Déjà vu for Aveo and tivozanib
As the plot thickens around the trigger for Aveo’s equity raise, the EU regulator considers pulling the group's renal cancer drug from the market.
AACR 2019 – Entinostat turns Syndax’s frown upside down
After two checkpoint combo trials flopped last month Syndax celebrates an unexpected win in a third.
AACR 2019 – Chi-Med has savolitinib filing in its sights
A patient death notwithstanding, Chi-Med reckons results from the Tatton study justify its US registration strategy.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.